Circulating Nucleosomes as a Novel Biomarker for Sepsis: A Scoping Review
Circulating nucleosome levels are commonly elevated in physiological and pathological
conditions. Their potential as biomarkers for diagnosing and prognosticating sepsis remains …
conditions. Their potential as biomarkers for diagnosing and prognosticating sepsis remains …
[HTML][HTML] Expression of Tissue Factor and Platelet/Leukocyte Markers on Extracellular Vesicles Reflect Platelet–Leukocyte Interaction in Severe COVID-19
T Eichhorn, R Weiss, S Huber… - International Journal of …, 2023 - mdpi.com
Severe COVID-19 is frequently associated with thromboembolic complications. Increased
platelet activation and platelet–leukocyte aggregate formation can amplify thrombotic …
platelet activation and platelet–leukocyte aggregate formation can amplify thrombotic …
[HTML][HTML] Evaluation of bovine coronavirus in Korean native calves challenged through different inoculation routes
HC Cho, Y Kim, YI Cho, J Park, KS Choi - Veterinary Research, 2024 - ncbi.nlm.nih.gov
Bovine coronavirus (BCoV) is a pneumoenteric virus that can infect the digestive and
respiratory tracts of cattle, resulting in economic losses. Despite its significance, information …
respiratory tracts of cattle, resulting in economic losses. Despite its significance, information …
[图书][B] Inflammatory Profiles and Immune Responses to High-Altitude Acclimatization
K Pham - 2023 - search.proquest.com
High altitude is a physiologically stressful environment due to oxygen limitation and low
atmospheric pressure. Despite these conditions, over 160 million people live, work, or travel …
atmospheric pressure. Despite these conditions, over 160 million people live, work, or travel …
[PDF][PDF] DEVELOPMENT OF IMMUNOASSAYS FOR SPECIFIC CLASSICAL AND LECTIN PATHWAY ACTIVATION MARKERS
L Hurler - 2023 - repo.lib.semmelweis.hu
TABLE OF CONTENTS CORVOS STATEMENT.................................................................................
.......... 2 STATEMENT OF ORIGINALITY.......................................................................... 4 …
.......... 2 STATEMENT OF ORIGINALITY.......................................................................... 4 …